AGN-190584

DRUG4 trials

Sponsors

Allergan, AbbVie, Gordon Schanzlin New Vision

Conditions

Presbyopia

Phase 2

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

CompletedNCT02197806

AllerganPresbyopia

Start: 2014-07-31End: 2014-11-30Updated: 2015-12-03

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

WithdrawnNCT05393089

AllerganPresbyopia

Start: 2022-06-09End: 2023-04-04Updated: 2022-06-29

Phase 3

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age

CompletedNCT04837482

AbbViePresbyopia

Start: 2021-05-14End: 2021-12-07Updated: 2024-10-10

Phase 4

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

WithdrawnNCT05624320

Gordon Schanzlin New VisionPresbyopia

Start: 2022-12-01End: 2023-06-30Updated: 2024-04-09

Related Papers

Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance

Clinical and Experimental Optometry2023-12-036 citations

Safety and Efficacy of AGN-190584 in Individuals With Presbyopia

JAMA Ophthalmology2022-03-0345 citations